Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Pattison

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|June 17, 2021
Clinical insignificance of [<sup>18</sup>F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluationEvyn G Arnfield, Paul A Thomas, Matthew J Roberts, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 29, 2024
First-in-Human <sup>212</sup>Pb-PSMA-Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate CancerMatthew R Griffiths, David A Pattison, Melissa Latter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 12, 2020
Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancerMatthew J Roberts, Andrew Morton, Peter Donato, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 23, 2020
<sup>68</sup>Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancerMatthew J Roberts, Andrew Morton, Peter Donato, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 12, 2021
Prospective intra-individual blinded comparison of [<sup>18</sup>F]PSMA-1007 and [<sup>68</sup> Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancerDavid A Pattison, Maciej Debowski, Brook Gulhane, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 3, 2021
Correction to: Prospective intra‑individual blinded comparison of [<sup>18</sup>F]PSMA‑1007 and [<sup>68</sup> Ga]Ga‑PSMA‑11 PET/CT imaging in patients with confirmed prostate cancerDavid A Pattison, Maciej Debowski, Brook Gulhane, et al.
Endocrine-Related Cancer|May 27, 2025
Peptide receptor radionuclide therapy in malignant insulinomaDavid A Pattison, Grace Kong, Timothy Akhurst, et al.
BJU International|March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.
EJNMMI Research|July 24, 2025
A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancerMatthew J Roberts, Natasha A Roberts, Anita Pelecanos, et al.
Urologic Oncology|December 13, 2021
The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparisonArsalan Tariq, Michael Kwok, Adam Pearce, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
European Journal of Nuclear Medicine and Molecular Imaging|June 17, 2021
Clinical insignificance of [<sup>18</sup>F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluationEvyn G Arnfield, Paul A Thomas, Matthew J Roberts, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 29, 2024
First-in-Human <sup>212</sup>Pb-PSMA-Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate CancerMatthew R Griffiths, David A Pattison, Melissa Latter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 12, 2020
Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancerMatthew J Roberts, Andrew Morton, Peter Donato, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 23, 2020
<sup>68</sup>Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancerMatthew J Roberts, Andrew Morton, Peter Donato, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 12, 2021
Prospective intra-individual blinded comparison of [<sup>18</sup>F]PSMA-1007 and [<sup>68</sup> Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancerDavid A Pattison, Maciej Debowski, Brook Gulhane, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 3, 2021
Correction to: Prospective intra‑individual blinded comparison of [<sup>18</sup>F]PSMA‑1007 and [<sup>68</sup> Ga]Ga‑PSMA‑11 PET/CT imaging in patients with confirmed prostate cancerDavid A Pattison, Maciej Debowski, Brook Gulhane, et al.
Endocrine-Related Cancer|May 27, 2025
Peptide receptor radionuclide therapy in malignant insulinomaDavid A Pattison, Grace Kong, Timothy Akhurst, et al.
BJU International|March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.
EJNMMI Research|July 24, 2025
A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancerMatthew J Roberts, Natasha A Roberts, Anita Pelecanos, et al.
Urologic Oncology|December 13, 2021
The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparisonArsalan Tariq, Michael Kwok, Adam Pearce, et al.
Pageof 8